Compare Bristol-Myers Squibb Co (BMY) vs SPDR Gold Trust (GLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs SPDR Gold Trust — how do they compare? Bristol-Myers Squibb Co trades at $58.54 (market cap $116.30B), while SPDR Gold Trust trades at $371.4. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while SPDR Gold Trust pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| BMY | GLD | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $495.90 |
52-Week Low | $42.60 | $300.96 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
GLD trades at $367.13, down 2.59% amid a bearish technical setup with 19 sell signals versus 2 buys. Support lies at $365 and $363, while resistance is at $370 and $374. Recent news highlights gold's volatility from inflation data and Fed policy shifts, with prices testing key levels after softer CPI provided temporary relief.
The outlook remains cautious as rising yields and dollar strength pressure gold. Near-term direction hinges on Fed rate expectations and geopolitical tensions. Risks include prolonged high rates eroding gold's appeal, while potential inflation spikes or market instability could renew safe-haven demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
